UK Edition. Click here for US version.
RENNIE ORANGE FLAVOUR
Active substance(s): CALCIUM CARBONATE
NAME OF THE MEDICINAL PRODUCT
Rennie Orange Flavour
QUALITATIVE AND QUANTITATIVE COMPOSITION
Also contains sucrose and Ponceau 4R (E124)
For full list of excipients, see section 6.1.
A square orange occasionally spotted tablet with rounded corners, bevelled edges and
For the symptomatic relief of indigestion, heartburn, hyperacidity, flatulence,
upset stomach, dyspepsia, biliousness, over indulgence in food and drink,
indigestion during pregnancy, acid indigestion, nervous indigestion.
Posology and method of administration
Tablets to be taken orally, sucked or chewed.
children over 12
Two tablets to be sucked or chewed as a single dose,
preferably to be taken one hour after meals and before
going to bed but also in between in case of heartburn or
gastric pain. A maximum daily dose of 8 g calcium
carbonate, corresponding to 16 tablets, a day must not be
Not recommended for children under 12 years.
As with all antacids, if symptoms persist despite 14 days of continuous
therapy, diagnostic measures are strongly recommended in order to rule out a
more serious disease.
Rennie should not be administered to patients with:
• Hypersensitivity to any of the ingredients of the product
• Hypercalcaemia and/or conditions resulting in hypercalcaemia
• Nephrolithiasis due to calculi containing calcium deposits
• Severe renal insufficiency
Special warnings and precautions for use
Prolonged use should be avoided.
The stated dose should not be exceeded. If, after 14 days of treatment,
symptoms persist or only partly disappear, the patient should consult a doctor.
Caution should be exercised in patients with mild to moderate impairment of
renal function (See section 4.3 – contraindication in severe renal
insufficiency). If Rennie is used in such patients, plasma calcium and
phosphate levels should be regularly monitored.
Long term use at high doses can result in undesirable effects such as
hypercalcaemia and milk-alkali syndrome, especially in patients with renal
Rennie should not be used in patients with hypercalciuria (see also section
4.3). Prolonged use increases the risk of formation of renal calculi.
This product should not be taken with large amounts of milk or dairy products.
Patients with rare hereditary problems of fructose intolerance, glucosegalactose malabsorption or sucrase-isomaltase insufficiency should not take
Ponceau 4R (E124) may cause allergic reactions.
Interaction with other medicinal products and other forms of interaction
Changes in gastric acidity, such as that caused by the ingestion of antacids, can
affect the rate and degree to which some concurrently administered medicines
It has been shown that antacids which contain calcium may form complexes
with certain substances e.g., antibiotics (such as tetracyclines and
quinolones), and cardiac glycosides (e.g. digoxin), levothyroxine, and
eltrombopag, resulting in decreased absorption. This should be borne in
mind when concomitant administration is considered.
Calcium salts can impede the absorption of phosphates, fluorides and
Thiazide diuretics reduce the urinary excretion of calcium. Due to an
increased risk of hypercalcaemia, serum calcium should be regularly
monitored during concomitant use of thiazide diuretics.
Therefore it is preferable to take the antacid separately from other drugs,
allowing at least 4 hours before or after taking eltrombopag and a 1-2 hour
interval for all other drugs.
Fertility, pregnancy and lactation
No increased risk of congenital defects has been observed after the use of this product
during pregnancy and it can be used during pregnancy and lactation if taken as
instructed but prolonged intake of high dosages should be avoided. Pregnant women
should limit the use of these products to the maximum recommended daily doses (see
During pregnancy and lactation, it has to be taken into account that the tablets provide
a substantial amount of calcium in addition to dietary calcium intake. For this reason,
pregnant women should strictly limit their use of tablets to the maximum
recommended daily dose and avoid concomitant, excessive intake of milk and dairy
products. This warning is to prevent calcium overload which might result in milkalkali syndrome.
Effects on ability to drive and use machines
No effects on ability to drive and use machines have been observed.
The listed adverse drug reactions are based on spontaneous reports, thus an
organisation according to CIOMS III categories of frequency is not possible.
Immune System Disorders:
Hypersensitivity reactions have very rarely been reported. Clinical
symptoms may include rash, urticaria, angioedema and anaphylaxis.
Metabolism and Nutrition Disorders:
Especially in patients with impaired renal function, prolonged use of
high doses can result in hypercalcaemia and alkalosis which may give
rise to gastric symptoms and muscular weakness (see below).
Nausea, vomiting, stomach discomfort and diarrhoea may occur.
Musculoskeletal and Connective Tissue Disorders:
Muscular weakness may occur.
Undesirable effects occurring in the context of milk-alkali syndrome (see
Ageusia may occur in the context of milk-alkali syndrome.
General Disorders and Administration Site Conditions:
Calcinosis and asthenia may occur in the context of milk-alkali
Nervous System Disorders:
Headache may occur in the context of milk-alkali syndrome.
Renal and Urinary Disorders:
Azotemia may occur in the context of milk-alkali syndrome.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal
product is important. It allows continued monitoring of the benefit/risk balance
of the medicinal product. Healthcare professionals are asked to report any
suspected adverse reactions via the Yellow Card Scheme at:
Especially in patients with impaired renal function, prolonged use of high doses of
calcium carbonate can result in renal insufficiency, hypercalcaemia and alkalosis
which may give rise to gastrointestinal symptoms (nausea, vomiting, constipation)
and muscular weakness. In these cases, the intake of the product should be stopped
and adequate fluid intake encouraged. In severe cases of overdosage (e.g. milk-alkali
syndrome), a health care professional must be consulted because other measures of
rehydration (e.g. infusions) might be necessary.
Pharmacotherapeutic Classification: Antacids
Calcium carbonate: A02AC01
Calcium carbonate reacts with excess acid in the gastric juice to produce soluble
CaCl2 + H2O + CO2
Calcium carbonate has a rapid and powerful neutralising action.
In healthy volunteers, a significant increase in the pH of stomach contents above
baseline pH was achieved between 1 and 6 minutes after dosing.
A small amount of calcium may be absorbed, but in healthy subjects is usually
rapidly excreted by the kidney. The soluble chloride produced by the reaction
of calcium with gastric acid reacts, in turn, with intestinal, biliary and
pancreatic secretions to form insoluble salts, which are excreted in the faeces.
Preclinical safety data
There is no information of relevance to the safety assessment in addition to what is
stated in other parts of the Summary of Product Characteristics.
List of excipients
Sucrose Pregelatinised Maize Starch Potato Starch Anhydrous Citric Acid
Purified Talc Magnesium Stearate Saccharin Quinoline Yellow (E104) Ponceau
4R (E124) Orange Flavour.
Special precautions for storage
Do not store above 25°C
Nature and contents of container
Tablets are packed in clear styrolex bottles with polypropylene lids, containing
30, 70, 100, or 150 tablets.
Alternatively, 8 tablets are roll wrapped in laminated foil.
Alternatively, tablets are packed in aluminium foil/pvc blister strips with 4, 8,
or 12 tablets per strip. 1, 2, 3, 4, 6, 8, 10 or 12 strips are
Placed in a cardboard carton (8, 12, 24, 32, 48, 64, 72, 80, 96, or 120 tablets
per carton), which may contain one or more cut-out "windows".
Alternatively one strip of 8 tablets is presented in a cardboard sample wallet
which may contain one or more cut-out "windows".
Pack sizes: 8, 12, 24, 30, 32, 48, 60, 64, 70, 72, 80, 96,100, 120, 150.
Special precautions for disposal
MARKETING AUTHORISATION HOLDER
Bayer plc, Consumer Care Division
MARKETING AUTHORISATION NUMBER(S)
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
DATE OF REVISION OF THE TEXT